Welcome to our dedicated page for Accolade news (Ticker: ACCD), a resource for investors and traders seeking the latest updates and insights on Accolade stock.
Accolade, Inc. (ACCD) delivers technology-powered healthcare solutions that combine virtual care with expert clinical navigation. This news hub provides investors and industry professionals with essential updates on the company’s strategic initiatives and market position.
Track official press releases, earnings announcements, and operational developments through our curated collection. Find timely information on healthcare partnerships, service expansions, and technology innovations that shape Accolade’s role in personalized care solutions.
Our repository includes updates across key business areas: financial results, leadership changes, clinical program enhancements, and regulatory milestones. Each entry is sourced directly from company communications to ensure accuracy and compliance.
Bookmark this page for streamlined access to ACCD’s evolving story in healthcare technology. Monitor how the company’s unique blend of digital tools and clinical expertise continues to redefine employer-sponsored and individual healthcare navigation.
Accolade, Inc. (NASDAQ: ACCD) will participate in the virtual 29th Annual Credit Suisse Healthcare Conference on November 11, 2020, at 10:15 a.m. E.T. The event includes a fireside chat presentation. Audio webcast and materials will be available on their investor relations website. Accolade offers personalized health solutions using technology to help users navigate healthcare and benefits with ease, maintaining over 90% consumer satisfaction and an NPS of 60.
Accolade, Inc. (Nasdaq: ACCD) announced the closing of its public offering of 5,750,000 shares of common stock at $38.50 per share, raising approximately $221.4 million in gross proceeds. This includes the full exercise of the underwriters' option to purchase an additional 750,000 shares. The offering was managed by Goldman Sachs, Morgan Stanley, and BofA Securities, among others. The funds will support Accolade's growth in personalized health solutions, aiding individuals in navigating the healthcare system.
Accolade, Inc. announced a public offering of 5,000,000 shares of common stock priced at $38.50 each, with an anticipated closing date of October 26, 2020. The underwriters have an option to purchase an additional 750,000 shares. Proceeds will be allocated for general corporate purposes, including working capital, operating expenses, and strategic investments. Goldman Sachs, Morgan Stanley, and BofA Securities are the joint book-running managers for the offering.
Accolade has filed a registration statement with the SEC for a public offering of 4,500,000 shares of common stock, with an option for underwriters to purchase an additional 675,000 shares. The offering price is yet to be determined and is subject to market conditions. Proceeds will be used for general corporate purposes including working capital, operating expenses, and strategic investments. Joint book-running managers include Goldman Sachs, Morgan Stanley, and BofA Securities. The registration statement is pending effectiveness.
Accolade, Inc. reported fiscal Q2 2021 revenue of $36.8 million, reflecting a 24% increase from $29.7 million in Q2 2020, fueled by rising customer additions across various segments. Despite ongoing challenges from the COVID-19 pandemic, CEO Rajeev Singh emphasized the company's strong financial performance and positive momentum. Notably, adjusted gross profit grew 23% to $15.9 million. However, the company experienced a net loss of $15.4 million, slightly higher than the previous year's $15 million loss. The outlook for the full year has been raised, indicating confidence in future growth.
Accolade (NASDAQ: ACCD) will release its fiscal Q2 2021 financial results on October 14, 2020, after markets close. The company will host a conference call at 5:00 p.m. EDT on the same day to discuss the results. Accolade offers personalized health solutions, assisting users in navigating the healthcare system and workplace benefits. The company boasts over 90% consumer satisfaction and a Net Promoter Score of 60, emphasizing its commitment to enhancing healthcare experiences.
Accolade, Inc. (NASDAQ: ACCD) will participate in the virtual Morgan Stanley 18th Annual Healthcare Conference on September 14, 2020, at 1:30 p.m. E.T. The event will include a fireside chat presentation, and an audio webcast along with related materials will be accessible at ir.accolade.com.
Accolade offers personalized health and benefits solutions aimed at helping users navigate the healthcare system more effectively. The company boasts high consumer satisfaction ratings, exceeding 90%, and a Net Promoter Score (NPS) of 60.
Accolade, Inc. (NASDAQ: ACCD) reported a fiscal Q1 2021 revenue of $35.9 million, representing a 25% increase from $28.8 million in the same quarter last year. The growth was attributed to new customer acquisitions across various segments. The company introduced a pilot program with the Defense Health Agency, marking its entry into the federal government sector. Although the net loss decreased to $(14.0) million from $(15.9) million in Q1 2020, the adjusted gross margin fell to 38.3%. The company provided guidance for Q2 2021 and full-year fiscal 2021.
